Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 1
Submit an article Journal homepage
1,473
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Activating STAT5B mutations can cause both primary hypereosinophilia and lymphocyte-variant hypereosinophilia

Kavita Umraua Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Ken Naganumab Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
,
Qi Gaoa Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Ahmet Dogana Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Masahiro Kizakib Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
,
Mikhail Roshala Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
,
Ying Liua Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
&
Mariko Yabea Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
 show all
Pages 238-241 | Received 03 Jun 2022, Accepted 22 Sep 2022, Published online: 28 Oct 2022

References

  • Butt NM, Lambert J, Ali S, British Committee for Standards in Haematology, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553–572.
  • Valent P, Gleich GJ, Reiter A, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol. 2012;5(2):157–176.
  • Bain BH, Arber DA, Tefferi A, et al. Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement of rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J., editors. WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). Lyon: IARC; 2017. P. 71–80.
  • Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338(22):1592–1600.
  • Simon HU, Plotz SG, Dummer R, et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341(15):1112–1120.
  • Cross NCP, Hoade Y, Tapper WJ, et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2019;33(2):415–425.
  • Sreedharanunni S, Jamwal M, Balakrishnan A, et al. Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-an entity with features of myelodysplastic syndrome/myeloproliferative neoplasm overlap. Leuk Res. 2022;112:106753.
  • Ma CA, Xi L, Cauff B, et al. Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood. 2017;129(5):650–653.
  • Andersson EI, Tanahashi T, Sekiguchi N, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016;128(20):2465–2468.
  • Pham HTT, Maurer B, Prchal-Murphy M, et al. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018;128(1):387–401.
  • Swerdlow SC, Harris NL, Jaffe ES, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). Lyon: IARC; 2017.
  • Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264.
  • McKinney M, Moffitt AB, Gaulard P, et al. The genetic basis of hepatosplenic T-cell lymphoma. Cancer Discov. 2017;7(4):369–379.
  • Pardanani A, Lasho T, Wassie E, et al. Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia. 2016;30(9):1924–1926.
  • Eisenberg R, Gans MD, Leahy TR, et al. JAK inhibition in early-onset somatic, nonclonal STAT5B gain-of-function disease. J Allergy Clin Immunol Pract. 2021;9(2):1008–1010 e1002.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.